22
2020-05
Kintor Pharmaceutical successfully listed on HKEX today
Kintor Pharmaceutical Limited (Stock Code:9939.HK) has successfully been listed on the Main Board of the Stock Exchange of Hong Kong Limited on 22,May 2020.
16
2020-04
Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement
Suzhou Kintor Pharmaceutical ,Inc. ("Kintor Pharmaceutical ")and Sinopharm Holding Co., Ltd. signed the strategic cooperation agreement on the innovation of topical drug Pyrilutamide (KX-826) in Shanghai. Both sides carry out all-round cooperation on patient-centered product design, future business channel development and terminal services, so as to prepare for future market development and better service for patients.
17
2020-02
Suzhou Kintor Obtained Approval to Conduct Clinical Trials for SMO Antagonists in China
On February 17, 2020, National Medical Products Administration officially granted the clinical trials notification to Suzhou Kintor Pharmaceuticals, Inc.(hereinafter referred to as “Suzhou Kintor") and agreed to approve clinical trials to be conducted on the SMO antagonist, GT1708F.
13
2019-12
Ms. Lu Yan Serves as Kintor's Chief Financial Officer
[Suzhou, December 13, 2019] Kintor Pharmaceutical Limited and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls
25
2019-10
[Suzhou, China, October 25, 2019] Kintor Pharmaceutical Limited (the parent company of Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor")) and its subsidiaries (the "Group")announced completion of a financing of USD45 million in September 2019, which was a new round of financing after Series C investment of RMB288 million in February 2018. This round of investment was led by the Shanghai Free Trade Zone Fund, followed by Huajin Capital, CCB Technological Innovation Fund, Yicheng Hongtai, Yirongchuang and Guangzhou Chengfa. The original investor, Highlight Medical, also participated in this round of investment.
20
2019-08
mTOR Inhibitor Developed by Suzhou Kintor Obtained Approval for Clinical Trials in China
[Suzhou, August 20, 2019] National Medical Products Administration officially granted a clinical trial approval to Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") on commencement of clinical trials of the drug (GT0486) as an mTOR inhibitor. The drug (GT0486) is a novel mTORC1 / mTORC2 inhibitor (the second generation of mTOR inhibitor) which is indicated for advanced solid tumors. Currently, there is no second generation of mTOR inhibitors on the market in China, and there are huge unmet clinical needs in the research area.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn